Grace Therapeutics, Inc. lost $0.47 per diluted share in fiscal year 2026. This represents an increase of 40.5% from the prior fiscal year. Over the trailing 12 months, Q2 FY2026 through Q1 FY2027, the same line adds up to a loss of $1.17 per diluted share. The table below carries 8 fiscal years, from 2019 to 2026, and the quarters Grace Therapeutics, Inc. has filed alongside them.
FY2026 annual
EPS (Diluted)-$0.47
YoY+40.5%
Source SEC Filings (10-K/10-Q)Latest period Q1 FY2027, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
GRCE EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Grace Therapeutics, Inc.'s diluted earnings per share in fiscal year 2026?
Grace Therapeutics, Inc. lost $0.47 per diluted share in fiscal year 2026.
How fast is Grace Therapeutics, Inc.'s diluted earnings per share growing?
Grace Therapeutics, Inc. (GRCE) diluted earnings per share rose by 40.5% year over year, from -$0.79 to -$0.47 in fiscal year 2026.
What is Grace Therapeutics, Inc.'s diluted earnings per share over the last twelve months?
Grace Therapeutics, Inc. (GRCE) reported a loss of $1.17 per diluted share over the trailing 12 months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings.
What was Grace Therapeutics, Inc.'s diluted earnings per share in the most recent quarter?
Grace Therapeutics, Inc. (GRCE) reported -$0.91 in diluted earnings per share in Q1 2027. This represents a decrease of 333.3% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Grace Therapeutics, Inc. (GRCE) reported on that line in every period on record.
